Assessment of symptomatic and neuroprotective efficacy of Mucuna pruriens seed extract in rodent model of Parkinson's disease

被引：0
|
作者：
Pinna, A. [1 ,2 ]
Pontis, S. [2 ]
Schintu, N. [2 ]
Simola, N. [2 ]
Kasture, S. [3 ]
Morelli, M. [1 ,2 ]
机构：
[1] CNR, Inst Neurosci, Cagliari, Italy
[2] Univ Cagliari, Dept Toxicol, Cagliari, Italy
[3] MGVs Pharm Coll, Dept Pharmacol, Nasik, India
来源：
PARKINSONISM & RELATED DISORDERS | 2009年 / 15卷
关键词：
D O I：
10.1016/S1353-8020(09)70457-2
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P2.106
引用
收藏
页码：S117 / S117
页数：1
相关论文
共 50 条
  • [21] Mucuna pruriens in Parkinson's disease: a double blind clinical and pharmacological study
    Katzenschlager, R
    Evans, A
    Manson, A
    Patsalos, PN
    Ratnaraj, N
    Watt, H
    Timmermann, L
    Van der Giessen, R
    Lees, AJ
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2004, 75 (12): : 1672 - 1677
  • [22] Mucuna pruriens Seed Aqueous Extract Improved Neuroprotective and Acetylcholinesterase Inhibitory Effects Compared with Synthetic L-Dopa
    Kamkaen, Narisa
    Chittasupho, Chuda
    Vorarat, Suwanna
    Tadtong, Sarin
    Phrompittayarat, Watoo
    Okonogi, Siriporn
    Kwankhao, Pakakrong
    MOLECULES, 2022, 27 (10):
  • [23] Mucuna pruriens proves more effective than levodopa/carbidopa in Parkinson's disease animal model
    Manyam, BV
    Hussain, G
    NEUROLOGY, 1996, 46 (02) : 5117 - 5117
  • [24] Allantoin is the neuroprotective metabolite of inosine in a rodent model of Parkinson's disease
    Terpstra, B. T.
    Lipton, J. W.
    Collier, T. J.
    Muratsubaki, H.
    Levine, N. D.
    Wohlgenant, S.
    Strauss, A. D.
    Gombash, S. E.
    Sortwell, C. E.
    MOVEMENT DISORDERS, 2010, 25 (07) : S211 - S211
  • [25] Neuroprotective and Symptomatic Effects of Cannabidiol in an Animal Model of Parkinson's Disease
    Giuliano, Claudio
    Francavilla, Miriam
    Ongari, Gerardo
    Petese, Alessandro
    Ghezzi, Cristina
    Rossini, Nora
    Blandini, Fabio
    Cerri, Silvia
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (16)
  • [26] Mucuna pruriens in Parkinson's disease: A double-blind clinical and pharmacological study
    Katzenschlager, R
    Evans, A
    Manson, A
    Patsalos, P
    Ratnaraj, N
    Lees, AJ
    MOVEMENT DISORDERS, 2004, 19 : S249 - S249
  • [27] Mucuna pruriens: A new strategy for Parkinson's disease treatment in Africa. An update
    Cassani, E.
    Barichella, M.
    Cilia, R.
    Akpalu, A.
    Ofosu-Budu, K.
    Cham, M.
    Ferrario, E.
    Faceli, E.
    Zecca, L.
    Sparvoli, F.
    Privitera, G.
    De Marco, P.
    Zecchinelli, A.
    Bonetti, A.
    Iorio, L.
    Amboni, M.
    Cereda, E.
    Pezzoli, G.
    MOVEMENT DISORDERS, 2014, 29 : S136 - S137
  • [28] Beyond L-DOPA: Bioactives in Mucuna pruriens for the treatment of Parkinson's disease
    Hessler, Craig
    Niesen, Daniel
    Ma, Hang
    Seeram, Navindra
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2015, 250
  • [29] A Preliminary Investigation for Standardization of Hydroalcoholic Extract of Mucuna pruriens (Kapikaccu): An Important Drug Used to Treat Parkinson's Disease in Ayurveda
    Swamy, Gangadhara
    Holla, Rajendra
    Rao, Suresh R.
    JOURNAL OF HEALTH AND ALLIED SCIENCES NU, 2019, 9 (03): : 85 - 90
  • [30] DOSE- AND TIME-DEPENDENT THERAPEUTIC AND ADVERSE EFFECTS OF MUCUNA PRURIENS EXTRACT IN THE 6-OHDA RAT MODEL OF PARKINSON'S DISEASE
    Gramsbergen, J. B.
    Jorgensen, M.
    Christensen, L. P.
    JOURNAL OF NEUROCHEMISTRY, 2011, 118 : 142 - 143
12345